Rafael Amado
2015 - Adaptimmune Therapeutics
In 2015, Rafael Amado earned a total compensation of $2.9M as Chief Medical Officer at Adaptimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $149,111 |
|---|---|
| Option Awards | $2,379,693 |
| Salary | $331,358 |
| Other | $31,949 |
| Total | $2,892,111 |
Amado received $2.4M in option awards, accounting for 82% of the total pay in 2015.
Amado also received $149.1K in non-equity incentive plan, $331.4K in salary and $31.9K in other compensation.
Rankings
In 2015, Rafael Amado's compensation ranked 3,298th out of 13,638 executives tracked by ExecPay. In other words, Amado earned more than 75.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,298 out of 13,638 | 76th |
Division Manufacturing | 1,201 out of 5,190 | 77th |
Major group Chemicals And Allied Products | 439 out of 1,854 | 76th |
Industry group Drugs | 349 out of 1,528 | 77th |
Industry Biological Products, Except Diagnostic Substances | 60 out of 254 | 76th |
Source: SEC filing on April 28, 2017.
Amado's colleagues
We found two more compensation records of executives who worked with Rafael Amado at Adaptimmune Therapeutics in 2015.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019